Abstracts tagged "infection and rheumatic disease"

Abstract Number: 940 • 2018 ACR/ARHP Annual Meeting
Inactivated Influenza Vaccine Prevents Respiratory Infections and Improves All-Cause and Cause-Specific Mortality in Immunosuppressed People with Autoimmune Rheumatic Diseases: Propensity Score Adjusted Cohort Study Using Data from Clinical Practice Research Datalink
Georgina Nakafero¹, Matthew Grainge², Puja Myles², Christian Mallen³, Weiya Zhang¹, Michael Doherty⁴, Jonathan Nguyen-van-tam² and Abhishek Abhishek¹, ¹Academic Rheumatology, The University of Nottingham, Nottingham, United Kingdom, ²Epidemiology and Public Health, The University of Nottingham, Nottingham, United Kingdom, ³Research Institute for Primary Care and Health Sciences, Keele University, Keele, United Kingdom, ⁴The University of Nottingham, Nottingham, United Kingdom
Background/Purpose: To assess the effectiveness of inactivated influenza vaccine (IIV) in preventing influenza like illness (ILI), lower respiratory tract infection (LRTI), pneumonia, chronic obstructive pulmonary…
Abstract Number: 1350 • 2016 ACR/ARHP Annual Meeting
Asymptomatic Coccidioidomycosis in Patients with Rheumatic Disease: 8 Years of Experience
Usman Ajaz¹, Jeffrey R. Lisse², Neil M. Ampel³ and Dominick Sudano⁴, ¹Department of Medicine, University of Arizona, Tucson, AZ, ²Arizona Arthritis Center, University of Arizona, Tucson, AZ, ³Department of Infectious Disease, Southern AZ VA Medical Center, Tucson, AZ, ⁴Department of Rheumatology, University of Arizona, Tucson, AZ
Background/Purpose: Coccidioidomycosis (valley fever) is an endemic fungal infection that typically causes a self-limited pulmonary illness in the Southwestern United States,. Immunosuppressed patients are at…
Abstract Number: 837 • 2014 ACR/ARHP Annual Meeting
Progressive Multifocal Leukoencephalopathy Associated with Biologic Therapy in Rheumatic Diseases: Strengthening Association with Rituximab
Eamonn Molloy¹ and Leonard H. Calabrese², ¹St Vincent University Hospital, Dublin, Ireland, ²Rheumatic & Immunologic Dis, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose Progressive Multifocal Leukoencephalopathy (PML) is a rare and often fatal opportunistic infection recently associated with several biologic therapies. However, ascribing risk to individual therapies…
Abstract Number: 2172 • 2012 ACR/ARHP Annual Meeting
An Update of Management of Coccidioidomycosis in Patients On Biologic Response Modifiers and Disease-Modifying Antirheumatic Drugs
Susan Knowles¹, Dominick Sudano¹, Sara Taroumian², Neil M. Ampel³, John Galgiani⁴, Jeffrey R. Lisse¹ and Susan E. Hoover⁵, ¹Department of Rheumatology, University of Arizona, Tucson, AZ, ²Department of Rheumatology, University of California, Los Angeles, Los Angeles, CA, ³Infectious Disease, University of Arizona, Tucson, AZ, ⁴Valley Fever Center for Excellence, Tucson, AZ, ⁵Infectious Diseases, University of Arizona, Tucson, AZ
Background/Purpose: Coccidioidomycosis (valley fever) is an endemic fungal infection in the Southwestern United States which typically causes a self-limited pulmonary illness. Patients with rheumatic disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].